Plain-English translation of NCT04777175 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a retrospective study, which means researchers are looking back at the medical records of patients who already received immunotherapy treatment for advanced lung cancer. The study focuses on patients whose lung cancer has rare genetic mutations—like KRAS, ALK, ERBB2, MET, RET, or BRAF—to understand how well immunotherapy works for each type of mutation.
Most information about how immunotherapy works comes from patients with common genetic mutations in lung cancer. Very little is known about whether this treatment is effective for patients with rare mutations, so this study aims to fill that gap and help doctors make better treatment decisions in the future.
You likely qualify if…
You likely don't qualify if…
This is a retrospective study, so you would not visit a clinic or receive new treatment. Instead, researchers would review your existing medical records to see what immunotherapy you received and how your cancer responded to it. There are no additional visits, medications, or tests required—the study simply uses information that has already been collected as part of your regular cancer care.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Collaborators
Hunan Province Tumor Hospital
Enrollment target
~186 participants
Started
January 2023
Primary completion
January 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.